Royalty Pharma Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 35
Employees
  • Stock Symbol
  • RPRX
Stock Symbol
  • Investments
  • 34
  • Share Price
  • $37.87
  • (As of Tuesday Closing)

Royalty Pharma General Information

Description

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company's portfolio consists of royalties on more than 45 marketed therapies and four development-stage product candidates. The therapies in portfolio address therapeutic areas such as rare diseases, oncology, neurology, HIV, cardiology and diabetes, and are delivered to patients across both primary and specialty care settings.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 110 East 59th Street
  • Floor 33
  • New York, NY 10022
  • United States
+1 (212) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Royalty Pharma Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.87 $38.77 $37.65 - $56.50 $23B 607M 1.24M $1.97

Royalty Pharma Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2020 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
Revenue 1,900,000 1,900,000 1,794,612 1,658,934
EBITDA 2,731,587 1,806,637
Net Income 2,348,535 1,377,729
Total Assets 12,449,895 11,370,147
Total Debt 6,238,122 6,519,332
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Royalty Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical ind
Biotechnology
New York, NY
35 As of 2019
00.000
0.00 0000-00-00
00000000 00.000

000000 0

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000000000000
Foster City, CA
00000 As of 0000
00.000
0&0

00000 &

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserun
000000000000000
Kenilworth, NJ
00000 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Royalty Pharma Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 0&0
00000 & 00. Corporation Kenilworth, NJ 00000 00000000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
000000 Corporation New York, NY 00000 000000 - 000
0000 0000000 Corporation Bagsvaerd, Denmark 00000 000000000
You’re viewing 5 of 9 competitors. Get the full list »

Royalty Pharma Executive Team (18)

Name Title Board Seat Contact Info
Pablo Legorreta Chief Executive Officer & Chairman
Terrance Coyne Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
George Lloyd JD Executive Vice President & General Counsel, Legal
Jim Reddoch Ph.D Executive Vice President and Head of Research & Investments
Susannah Gray Executive Vice President, Finance and Strategy
You’re viewing 5 of 18 executive team members. Get the full list »

Royalty Pharma Board Members (9)

Name Representing Role Since
00000000000 0000 Self Executive Vice President & Vice Chairman 000 0000
00000 000000000 00.0 Self Board Member 000 0000
00000 000000000 Royalty Pharma Chief Executive Officer & Chairman 000 0000
0000 00000 Royalty Pharma Co-Founder & Chairman 000 0000
000 0000 00 Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Royalty Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Royalty Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Investments & Acquisitions (34)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000000 ( 20-Jul-2020 000000000 00000 00 00000 Buildings and Property 00000 000000000
0000000 (00000000 09-Jun-2020 0000000000 00000 Buildings and Property 00000 000000000
0000000 (000000000 05-Mar-2020 0000000000 0000 Buildings and Property 00000 000000000
0000000 05-Nov-2019 0000 00000 Pharmaceuticals 00000 000000000
Ligand (Promacta assets) 06-Mar-2019 Buyout/LBO 00000 Buildings and Property 00000 000000000
You’re viewing 5 of 34 investments and acquisitions. Get the full list »

Royalty Pharma Subsidiaries (1)

Company Name Industry Location Founded
0000000 Pharmaceuticals
To view Royalty Pharma’s complete subsidiaries history, request access »

Royalty Pharma Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000000 19-Jun-2018 0000 0000 Completed
  • 0000000 000000
Cypress Bioscience 15-Dec-2010 Buyout/LBO 00000 Completed
  • 2 buyers
To view Royalty Pharma’s complete exits history, request access »